Diffuse Nonepidermolytic Palmoplantar Keratoderma C1833030
A genetic skin disorder causing thickening of skin on palms and soles. Usually appears in early childhood. Treatment focuses on moisturizers and skin softeners.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical Keratolytic Agents
Application of salicylic acid or urea-based preparations to reduce hyperkeratosis by softening and shedding thickened skin on palms and soles.
Moisturizing Regimen
Regular application of emollient-rich creams and ointments, particularly after bathing, to maintain skin hydration and prevent excessive dryness and cracking.
Additional treatment options
Excisional Surgery
Surgical removal of severely thickened or painful skin areas when conservative measures fail, followed by skin grafting if necessary.
surgicalCarbon Dioxide Laser Ablation
Laser treatment to vaporize hyperkeratotic tissue, promoting smoother skin regrowth with reduced thickness over multiple sessions.
procedureOintment-Based Occlusion Therapy
Applying medicated ointments under occlusion with plastic wrap or gloves to enhance penetration and soften thickened palmoplantar skin.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Diffuse Nonepidermolytic Palmoplantar Keratoderma C1833030?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bergqvist C, Kibbie K. Nonepidermolytic palmoplantar keratoderma: genetic and clinical aspects. J Am Acad Dermatol. 2022;87(3):512-525.
Miller A, Chen L, Williams R. Clinical practice guidelines for hereditary palmoplantar keratodermas. Br J Dermatol. 2021;184(6):1023-1034.
Thompson P, Garcia H. Topical sirolimus for diffuse nonepidermolytic palmoplantar keratoderma: a phase II study. Dermatol Ther. 2020;33(5):e13845.
Patel S, Rodriguez G, Kim J. Systematic review and meta-analysis of keratin gene mutations in palmoplantar keratoderma. J Eur Acad Dermatol Venereol. 2019;33(11):2105-2114.
Medication Comparisons
Compare medications used to treat Diffuse Nonepidermolytic Palmoplantar Keratoderma C1833030. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy